JP2013526581A - ヘテロ環式フラビウイルス科ウイルス阻害剤 - Google Patents

ヘテロ環式フラビウイルス科ウイルス阻害剤 Download PDF

Info

Publication number
JP2013526581A
JP2013526581A JP2013511379A JP2013511379A JP2013526581A JP 2013526581 A JP2013526581 A JP 2013526581A JP 2013511379 A JP2013511379 A JP 2013511379A JP 2013511379 A JP2013511379 A JP 2013511379A JP 2013526581 A JP2013526581 A JP 2013526581A
Authority
JP
Japan
Prior art keywords
aryl
alkyl
group
compounds
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013511379A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013526581A5 (enExample
Inventor
カイラ ビヨンソン，
スティーブン エス． ボンディー，
ユー−チュル チョイ，
チェン−フン チョウ，
ルチカ ミシラ，
ジェイムズ ディー． トリンクル，
ウィンストン シー． ツェ，
ランダール ダブリュー． ビビアン，
Original Assignee
ギリアード サイエンシーズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ギリアード サイエンシーズ， インコーポレイテッド filed Critical ギリアード サイエンシーズ， インコーポレイテッド
Publication of JP2013526581A publication Critical patent/JP2013526581A/ja
Publication of JP2013526581A5 publication Critical patent/JP2013526581A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2013511379A 2010-05-21 2011-05-20 ヘテロ環式フラビウイルス科ウイルス阻害剤 Pending JP2013526581A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34721510P 2010-05-21 2010-05-21
US61/347,215 2010-05-21
PCT/US2011/037305 WO2011146817A1 (en) 2010-05-21 2011-05-20 Heterocyclic flaviviridae virus inhibitors

Publications (2)

Publication Number Publication Date
JP2013526581A true JP2013526581A (ja) 2013-06-24
JP2013526581A5 JP2013526581A5 (enExample) 2014-07-03

Family

ID=44318079

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013511379A Pending JP2013526581A (ja) 2010-05-21 2011-05-20 ヘテロ環式フラビウイルス科ウイルス阻害剤

Country Status (6)

Country Link
US (1) US8815858B2 (enExample)
EP (1) EP2571882A1 (enExample)
JP (1) JP2013526581A (enExample)
CA (1) CA2797872A1 (enExample)
NZ (1) NZ603310A (enExample)
WO (1) WO2011146817A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8580842B2 (en) 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
US20080167286A1 (en) 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
SI2094702T1 (sl) 2006-12-14 2016-03-31 Gilead Sciences, Inc. Virusni inhibitorji
EP2231643B1 (de) * 2007-12-07 2012-10-31 Abbott GmbH & Co. KG Amidomethyl-substitutierte Oxindol-Derivate und ihre Verwendung zur Herstellung eines Medikaments zur Behandlung von Vasopressin-abhängigen Erkrankungen
CN101952276B (zh) 2007-12-07 2014-10-22 Abbvie德国有限责任两合公司 5-卤素取代的羟吲哚衍生物和其用于治疗加压素依赖性疾病的用途
US8703774B2 (en) 2007-12-07 2014-04-22 AbbVie Deutschland GmbH & Co. KG Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases
CN102026995B (zh) 2007-12-07 2014-10-29 Abbvie德国有限责任两合公司 5，6-二取代的羟吲哚衍生物和其用途
RS56654B8 (sr) 2009-05-13 2021-06-30 Gilead Pharmasset Llc Antiviralna jedinjenja
WO2010138600A2 (en) 2009-05-29 2010-12-02 Abbott Laboratories Pharmaceutical compositions for the treatment of pain
CN103842369A (zh) * 2011-03-31 2014-06-04 埃迪尼克斯医药公司 用于治疗病毒感染的化合物和药物组合物
NZ729172A (en) 2013-01-31 2018-06-29 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
WO2014164533A1 (en) * 2013-03-11 2014-10-09 Vertex Pharmaceuticals Incorporated Methods of stereoselective synthesis of substituted nucleoside analogs
WO2014148451A1 (ja) * 2013-03-19 2014-09-25 日本農薬株式会社 縮合複素環化合物又はその塩類及び該化合物を含有する農園芸用殺虫剤並びにその使用方法
JP2016529293A (ja) 2013-08-27 2016-09-23 ギリアド ファーマセット エルエルシー ２つの抗ウイルス化合物の組合せ製剤
MX386981B (es) * 2014-08-15 2025-03-19 Chia Tai Tianqing Pharmaceutical Group Co Ltd Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll 7 (tlr7).
IL296496B2 (en) 2014-12-26 2024-10-01 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
BR112018015927A2 (pt) * 2016-02-03 2018-12-26 Quercegen Pharmaceuticals Llc método para o tratamento da infecção pelo vírus zika com composições contendo quercetina
EP4483875A3 (en) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
EP3455219A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
EP3641762B1 (en) 2017-06-20 2026-02-18 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
KR102626210B1 (ko) 2017-12-07 2024-01-18 에모리 유니버시티 N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도
US20220324880A1 (en) * 2019-06-10 2022-10-13 Kymara Therapeutics, Inc. Smarca inhibitors and uses thereof
CA3219397A1 (en) 2021-05-21 2022-11-24 Gilead Sciences, Inc. Tetracyclic compounds for the treatment of zika virus infection
JP7725617B2 (ja) 2021-05-21 2025-08-19 ギリアード サイエンシーズ， インコーポレイテッド ジカウイルス阻害剤としての五環式誘導体

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004534828A (ja) * 2001-06-22 2004-11-18 アルミラル プロデスファルマ ソシエダ アノニマ 新規６−フェニルジヒドロピロロピリミジンジオン誘導体
JP2006501306A (ja) * 2002-09-30 2006-01-12 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
JP2007509947A (ja) * 2003-10-31 2007-04-19 シーブイ・セラピューティクス・インコーポレイテッド Ａ２ｂアデノシン受容体アンタゴニスト
JP2007518720A (ja) * 2003-12-22 2007-07-12 カー・イュー・ルーベン・リサーチ・アンド・ディベロップメント イミダゾ［４，５−ｃ］ピリジン化合物および抗ウイルス治療の方法
JP2008508296A (ja) * 2004-07-27 2008-03-21 ギリアード サイエンシーズ， インコーポレイテッド イミダゾ［４，５−ｄ］ピリミジン、それらの使用および調製方法
WO2008133669A2 (en) * 2006-12-14 2008-11-06 Gilead Sciences, Inc. Viral inhibitors
WO2008154271A1 (en) * 2007-06-06 2008-12-18 Smithkline Beecham Corporation Chemical compounds
JP2009520763A (ja) * 2005-12-23 2009-05-28 ノバルティス アクチエンゲゼルシャフト Ｄｐｐ−ｉｖ阻害剤として有用な縮合ヘテロ環式化合物
WO2009111501A1 (en) * 2008-03-04 2009-09-11 Smithkline Beecham Corporation Derivatives of imidazo [4, 5-d] pyridazine and their use as anti-viral compounds

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
US5726302A (en) * 1989-09-15 1998-03-10 Gensia Inc. Water soluble adenosine kinase inhibitors
US5028608A (en) * 1989-12-11 1991-07-02 The Trustees Of Princeton University N-(6-Amino-(pyrrolo(2,3-d)pyrimidin-3-ylacyl) )-glutamic acid derivatives
US5248775A (en) * 1989-12-11 1993-09-28 The Trustees Of Princeton University Pyrrolo(2,3-d)pyrimidines
AU651835B2 (en) 1990-06-13 1994-08-04 Arnold Glazier Phosphorous prodrugs
EP0481214B1 (en) 1990-09-14 1998-06-24 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Prodrugs of phosphonates
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
GB0215293D0 (en) 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
NZ556624A (en) 2004-12-21 2010-06-25 Gilead Sciences Inc 5-((3-(2,4-trifluoromethyphenyl)isoxazol-5-yl)methyl)-2-(2-fluorophenyl)-5H-imidazo[4,5-c]pyridine and method of antiviral treatment
JP2008543888A (ja) 2005-06-24 2008-12-04 ギリアード サイエンシーズ， インコーポレイテッド ピリド（３，２−ｄ）ピリミジン、およびＣ型肝炎を治療するのに有用な医薬組成物
SG175604A1 (en) 2006-07-07 2011-11-28 Gilead Sciences Inc Novel pyridazine compound and use thereof
US8673929B2 (en) 2006-07-20 2014-03-18 Gilead Sciences, Inc. 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections
US10144736B2 (en) 2006-07-20 2018-12-04 Gilead Sciences, Inc. Substituted pteridines useful for the treatment and prevention of viral infections
US8338435B2 (en) 2006-07-20 2012-12-25 Gilead Sciences, Inc. Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections
WO2008009078A2 (en) 2006-07-20 2008-01-24 Gilead Sciences, Inc. 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
TW200840584A (en) 2006-12-26 2008-10-16 Gilead Sciences Inc Pyrido(3,2-d)pyrimidines useful for treating viral infections
UA99466C2 (en) 2007-07-06 2012-08-27 Гилиад Сайенсиз, Инк. Crystalline pyridazine compound

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004534828A (ja) * 2001-06-22 2004-11-18 アルミラル プロデスファルマ ソシエダ アノニマ 新規６−フェニルジヒドロピロロピリミジンジオン誘導体
JP2006501306A (ja) * 2002-09-30 2006-01-12 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
JP2007509947A (ja) * 2003-10-31 2007-04-19 シーブイ・セラピューティクス・インコーポレイテッド Ａ２ｂアデノシン受容体アンタゴニスト
JP2007518720A (ja) * 2003-12-22 2007-07-12 カー・イュー・ルーベン・リサーチ・アンド・ディベロップメント イミダゾ［４，５−ｃ］ピリジン化合物および抗ウイルス治療の方法
JP2008508296A (ja) * 2004-07-27 2008-03-21 ギリアード サイエンシーズ， インコーポレイテッド イミダゾ［４，５−ｄ］ピリミジン、それらの使用および調製方法
JP2009520763A (ja) * 2005-12-23 2009-05-28 ノバルティス アクチエンゲゼルシャフト Ｄｐｐ−ｉｖ阻害剤として有用な縮合ヘテロ環式化合物
WO2008133669A2 (en) * 2006-12-14 2008-11-06 Gilead Sciences, Inc. Viral inhibitors
WO2008154271A1 (en) * 2007-06-06 2008-12-18 Smithkline Beecham Corporation Chemical compounds
WO2009111501A1 (en) * 2008-03-04 2009-09-11 Smithkline Beecham Corporation Derivatives of imidazo [4, 5-d] pyridazine and their use as anti-viral compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN5013007030; ＮＡＳＡＫＩＮ: 'ＲＥＡＣＴＩＯＮＳ　ＯＦ　３，３，４，４-ＴＥＴＲＡＣＹＮＯＰＹＲＲＯＬＩＤＩＮＥＳ　ＷＩＴＨ　ＡＬＣＯＨＯＬＳ' ＣＨＥＭＩＳＴＲＹ　ＯＦ　ＨＥＴＥＲＯＣＹＣＬＩＣ　ＣＯＭＰＯＵＮＤＳ Ｖ２８　Ｎ１１, 1992, Ｐ１２５５-１２５９ *
JPN7015001634; Ｎｕｃｌｅｉｃ　Ａｃｉｄｓ　Ｓｙｍｐｏｓｉｕｍ　Ｓｅｒｉｅｓ Ｎｏ．５２, 2008, ｐｐ．６０３-６０４ *

Also Published As

Publication number Publication date
EP2571882A1 (en) 2013-03-27
NZ603310A (en) 2015-01-30
CA2797872A1 (en) 2011-11-24
WO2011146817A1 (en) 2011-11-24
US20130171102A1 (en) 2013-07-04
US8815858B2 (en) 2014-08-26

Similar Documents

Publication Publication Date Title
US8815858B2 (en) Heterocyclic flaviviridae virus inhibitors
JP6475280B2 (ja) 抗ウイルス治療用の２’−フルオロ置換カルバヌクレオシド類似体
EP2635588B1 (en) Condensed imidazolylimidazoles as antiviral compounds
JP6033362B2 (ja) 抗ウイルス治療のための２′−フルオロ置換カルバ−ヌクレオシド類似体
US8476225B2 (en) Antiviral compounds
CA3095528C (en) Antiviral compounds
US8455451B2 (en) 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
US7973013B2 (en) 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
EP2873665A1 (en) Antiviral compounds
AU2011255452A1 (en) Heterocyclic flaviviridae virus inhibitors
HK40002411A (en) Condensed imidazolylimidazoles as antiviral compounds
HK40002411B (en) Condensed imidazolylimidazoles as antiviral compounds
HK1188989B (en) Condensed imidazolylimidazoles as antiviral compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140519

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140519

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150529

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150617

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151113